Skip to content
2000
Volume 8, Issue 4
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

The management of HBV or HCV has improved dramatically over the last decade with the development of new drugs. This paper provides a review of new available and developing treatment options for HBV and HCV associated liver diseases. In the closer future the most realistic therapeutical option for most of the patients with HBV and HCV infection will be combination and/or long-term usage of the new, stronger antiviral drugs, if they maintain good safety profiles, achieve low resistance rates and will be available at lower prices.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955708783955917
2008-04-01
2025-09-08
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955708783955917
Loading

  • Article Type:
    Research Article
Keyword(s): adefovir; HBV; HCV; IFN; lamivudine; resistance; ribavirin; STAT-C
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test